Matrixyl

The Matrixyl evidence base cited here is 6 sources — 2 clinical, 2 preclinical, 1 review. Its strongest evidence is human — 2 clinical studies, most recently 2023 ("Double-blind, Randomized Trial on the Effectiveness of Acetylhexapeptide…"). Regulatory status: Cosmetic use (topical).

• Palmitoyl-KTTKS (Pal-KTTKS) functions as a matrikine — a collagen-derived signaling fragment that activates TGF-β receptors on dermal fibroblasts, stimulating dose-dependent synthesis of collagen types I, III, and IV, fibronectin, and glucosaminoglycans without the irritation profile of retinoids.
• A 12-week, double-blind, placebo-controlled split-face study in 93 women found 3 ppm Pal-KTTKS in moisturizer produced significant improvements in wrinkle depth and fine lines versus placebo on both quantitative imaging and expert grader assessment.
• Skin permeation research confirmed that the palmitoyl lipid anchor is essential: unmodified KTTKS does not cross the stratum corneum, while Pal-KTTKS distributes across all skin layers (4.2 µg/cm² in stratum corneum, 2.8 µg/cm² in epidermis), with greater enzymatic stability compared to the unmodified peptide.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.